Buscopan Special Precautions

Sugar-coated tablet: Check with the doctor or pharmacist before taking the medicine if: with a very fast heart rate or other heart problems; with a problem with the thyroid gland such as an overactive thyroid gland; with difficulty or pain passing water (urine) such as men with prostate problems; with constipation; with a fever.
If unsure if any of the previously mentioned apply, talk to the doctor or pharmacist before taking BUSCOPAN Tablets.
Check with the doctor or pharmacist straight away if with unexplained abdominal pain which persists or worsens or occurs with: fever; feeling sick; being sick; changes in bowel movements; abdominal tenderness; low blood pressure; feeling faint; or blood in bowel movements.
Important information about some of the ingredients of BUSCOPAN Tablets: BUSCOPAN Tablets contain sucrose. The patient should talk to the doctor before taking this medicine if told by the doctor that some sugars cannot be tolerated or digested.
Driving and using machines: Some people may have sight problems while taking this medicine. If this happens, wait until sight returns to normal before driving or using any tools or machines.
Injection: General: BUSCOPAN should not be taken on a continuous daily basis or for extended periods without investigating the cause of abdominal pain.
Patients intolerant of one belladonna alkaloid or derivative may also be intolerant of other belladonna alkaloids or derivatives such as hyoscine butylbromide.
After parenteral administration of BUSCOPAN, cases of anaphylaxis, including episodes of shock have been observed. As with all drugs causing such reactions, patients receiving BUSCOPAN by injection should be kept under observation.
Parenteral BUSCOPAN can cause serious and severe cardiac adverse reactions consisting of tachycardia and hypotension (see Cardiovascular as follows and Contraindications).
Cardiovascular: Parenteral BUSCOPAN can cause adverse reactions of tachycardia and hypotension, which may be more serious or more severe in patients with cardiac conditions such as coronary heart disease, cardiac arrhythmias, hypertension, and mitral stenosis, and in cardiac surgery. Monitoring of these patients is advised until conditions return to normal. Emergency equipment and personnel trained in its use must be readily available.
Parenteral BUSCOPAN should be used with caution in patients with cardiac conditions.
Parenteral BUSCOPAN is contraindicated in patients with tachycardia, angina, and cardiac failure (see Contraindications).
The increase in heart rate may also be undesirable in patients with unstable cardiovascular status in an acute hemorrhage situation.
In addition, exercise caution in patients inclined to tachyarrhythmia.
Gastrointestinal: Exercise caution in patients with reflux esophagitis or gastrointestinal tract obstructive disease (i.e., achalasia and pyloroduodenal stenosis) due to the ability of anticholinergics/systemic antispasmodics to decrease smooth muscle motility and tone resulting in gastric retention.
Anticholinergics may aggravate hiatal hernia associated with reflux esophagitis, myasthenia gravis or pyloric obstruction.
In patients with ulcerative colitis, large anticholinergic doses may suppress intestinal motility, possibly causing paralytic ileus or resulting in obstruction; also, use may precipitate or aggravate toxic megacolon.
In case severe, unexplained abdominal pain persists or worsens, or occurs together with symptoms like fever, nausea, vomiting, changes in bowel movements, abdominal tenderness, decreased blood pressure, fainting or blood in stool, medical advice should immediately be sought.
Genitourinary: Parenteral BUSCOPAN (hyoscine butylbromide) should be used with caution in patients with prostatic enlargement. BUSCOPAN may precipitate or aggravate urinary retention in patients with the following conditions: non-obstructive prostatic hypertrophy, urinary retention (or the predisposition to) or obstructive uropathy such as a bladder neck obstruction due to prostatic hypertrophy (see Contraindications).
Ophthalmologic: The parenteral administration of hyoscine butylbromide, particularly of higher doses, has been reported to cause transient disturbances of accommodation which recede spontaneously. Therefore, patients should be cautioned about potential visual problems and the need to exercise care while driving or operating machinery after receiving BUSCOPAN solution.
Therapy should be discontinued if the patient reports any unusual visual disturbances or pressure pain within the eyes.
The mydriatic effect of anticholinergics/systemic antispasmodics may result in increased intraocular pressure. BUSCOPAN should be used with caution in patients with angle-closure glaucoma or with this predisposition, as anticholinergics/systemic antispasmodics may precipitate an acute angle-closure glaucoma attack (see Contraindications).
Patients should seek urgent ophthalmological advice in case they should develop a painful eye with loss of vision after injection of BUSCOPAN.
Effects on ability to drive and use machines: No studies on the effects on the ability to drive and use machines have been performed. However, patients should be advised that they may experience undesirable effects such as accommodation disorder or dizziness during treatment with BUSCOPAN solution. Therefore, caution should be recommended when driving a car or operating machinery. If patients experience accommodation disorder or dizziness, they should avoid potentially hazardous tasks such as driving or operating machinery.
Use in Children: BUSCOPAN is not currently recommended for use in children.
Use in the Elderly: Geriatric patients are especially susceptible to the anticholinergic side effects of constipation, dryness of mouth and urinary retention (especially in males). If these side effects continue or are severe, discontinuation of medication should be considered.
Due care is necessary when anticholinergics are administered to geriatric patients due to the danger of precipitating undiagnosed glaucoma.
Administration of anticholinergics/systemic antispasmodics to elderly patients with intestinal atony or in debilitated patients may result in intestinal obstruction.